HRTX / All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Buy

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2023, it might be wort more_horizontal

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Jeff Cohen - Executive Direct more_horizontal

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to l more_horizontal

Monday, Heron announced the appointment of Craig Collard as Chief Executive Officer and Adam Morgan as Chairman. These two executives will replace out more_horizontal

Heron's cash position remains a concern. Zynrelef, the company's top-selling therapy for postoperative pain relief, had 2022 sales that were up 362%. more_horizontal

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants David Szekeres – Executive V more_horizontal

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 32% and 13.53%, respectively, for the quarter ended December 2022. Do the number more_horizontal

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Szekeres - EVP and COO more_horizontal